ARIAD Pharmaceutical, Inc.ARIA reported third-quarter 2016 loss of 14 cents per share, narrower than the Zacks Consensus Estimate of a loss of 19 cents and the year-ago loss of 29 cents. Higher U.S. Iclusig sales and lower costs …
NASDAQ9mon
The Aria mini by Digibit of Spain is a : 2TB HDD digital server ... 1 factory sealed …
We too rate the stock a sell but not only due to David’s insider stock sell but rather because our own advanced time …
Over the last few years, Ariad has been attempting to sell itself to a larger biopharmaceutical peer, but a deal failed to go through in the past because of management's internal valuation of the company's clinical and commercial assets. …
The newly-spun out drug business, Baxalta — which is building a 500-employee research and development in Cambridge — is reportedly in talks to buy one of the most longstanding biotechs in the state, Ariad Pharmaceuticals. Bloomberg …
The most recent short interest data has been released by the NASDAQ for the 07/31/2013 settlement date, which shows a 2,230,507 share increase in total short interest for ARIAD Pharmaceuticals, Inc. (NASD: ARIA), to 18,217,590, an …
The most recent short interest data has been released for the 01/13/2017 settlement date, which shows a 8,224,965 share decrease in total short interest for ARIAD Pharmaceuticals Inc (NASDAQ:ARIA), to 23,605,983, a decrease of 25.84% …
Ariad Pharmaceuticals had $304 million in cash and cash equivalents ... Don't be too late to the party -- click here for one stock to own when the Web goes dark.
On Friday, December 14, the FDA granted early and accelerated approval of Ariad's (NASDAQ:ARIA) further reaching tyrosine kinase inhibitor Iclusig (ponatinib) for the treatment of adult patients with chronic, accelerated or blast phase …